期刊文献+

JAK2基因突变与慢性髓系白血病易感性的meta分析

Meta analysis on association between JAK2 gene mutation and susceptibility to chronic myeloid leukemia
下载PDF
导出
摘要 目的:探讨JAK2 基因突变与慢性髓系白血病(CML)的关系。方法:检索中国知网(CNKI)、维普(VIP)、万方、PubMed、Web of Science、CBM数据库中关于JAK2 突变与CML关系的文章。检索时间截至2018年9月,由两位研究者独立按照纳入与排除标准筛选文献,提取资料后,用纽卡斯尔-渥太华量表(NOS)评分进行质量评价。采用Stata 11.0、RevMan 5.3软件进行meta分析。结果:共纳入15篇文章,包含总病例数1 684例,JAK2 基因突变104例(突变位点分别位于第12和第14号外显子编码序列的第1 849位碱基G被T取代)。Meta分析结果显示CML患者的JAK2 基因突变率为0.08[95%CI (0.05,0.11)],亚组分析显示费城染色体(Ph)和JAK2 是否突变、不同地区的突变分布、外显子的突变位点是异质性的主要来源。结论:慢性髓系白血病细胞JAK2 基因外显子12和14突变、突变体JAKV617F 的存在可能促使CML的发生。 OBJECTIVE:To investigate the association between JAK2 gene mutation and development of chronic myeloid leukemia (CML). METHODS: A systematic literature searches of CNKI, VIP, Wanfang, PubMed,Web of Science and CBM databases were conducted in September 2018. The identified publications were screened for inclusion and exclusion criteria by two researchers independently. Data were extracted from selected papers and evaluated for quality using a modified NOS score. Meta-analyses were performed by using the Stata 11.0 and RevMan 5.3 software. RESULTS:A total of 15 articles were selected which included 1 684 cases and 104 mutations (JAK2V617F mutation is characterized by a G to T transversion at nucleotide 1 849 in exon 12 or exon 14 of the gene). Meta-analyses show that the mutation rate of JAK2 in CML patients was 0.08 [95%CI (0.05,0.11)]. Subgroup analyses show that the main reason for heterogeneity of whether Ph and JAK2 mutations involved different regions and exon mutation site. CONCLUSION:The JAK2 exon 12 and 14 mutations and mutant JAKV617F were associated with the development of CML.
作者 杨谨如 秦露露 朱勇飞 YANG Jinru;QIN Lulu;ZHU Yongfei(Department of Preventive Medicine,Medical School,Hunan NormalUniversity,Changsha 410013,Hunan,China)
出处 《癌变.畸变.突变》 CAS 2019年第3期231-237,共7页 Carcinogenesis,Teratogenesis & Mutagenesis
关键词 JAK2 基因突变 慢性髓系白血病 META分析 JAK2 gene mutation chronic myeloid leukemia meta-analysis
  • 相关文献

参考文献4

二级参考文献40

  • 1Lay M, Mariappan R, Gotilb J, et al. Detection of the JAK2 V617F Mutation by LightCycler PCR and Probe Dissociation Analysis. J Mol Diagn, 2006, 8:330-334.
  • 2James C, Ugo V, Casadevall N, et al. A JAK2 mutation in myeloproliferafive disorders: pathogenesis and therapeutic and scientific prospects. Trends Mol Med, 2005, 11 : 546-554.
  • 3James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 2005, 434:1144-1148.
  • 4Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 2005, 7:387-397.
  • 5Sehindler CW. JAK-STAT signaling in human disease. J Clin Invest, 2002, 109 : 1133-1137.
  • 6Olsen RJ, Tang Z, Farkas DH, et al. Detection of the JAK2V617F Mutation in Myeloproliferative Disorders by Melting Curve Analysis Using the Light Cycler System. Arch Pathol Lab Med, 2006,130: 997-1003.
  • 7Scott LM, Campbell PJ, Baxter EJ, et al. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood, 2005, 106:2920-2921.
  • 8Vardiman JW,Hams NL,Brunning RD.World Health Organization (WHO) classification of the myeloid neoplasms.Blood,2002,100:2292-2302.
  • 9Kralovics R,Passamonti F,Buser AS,et al.A gain-of-function mutation of JAK2 in myeloproliferative disorders.N Engl J Med,2005,352:1779-1790.
  • 10John MG,Junia VM.Chronic myeloid leukemia-advances in biology and new approaches to treatment.N Engl J Med,2003,349:1451-1464.

共引文献923

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部